Drugs / AZD8701
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04504669 | Aug 2020 → Oct 2024 | cervical cancer, clear cell renal carcinoma, gastroesophageal cancer, head and neck squamous cell carcinoma +4 | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-03-14 | AstraZeneca | Results AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗
Preclinical research on the activity of ASO AZD8701 (ION-AZ7), showing that inhibiting FOXP3 may limit immunosuppressive functions and induce tumour regression (Abstract #2713) |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-03-14 | AstraZeneca | AstraZeneca showcases next-generation Oncology pipeline addressing unmet patient needs at AACR Annual Meeting astrazeneca.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD8701 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04504669 ↗ |
| Route | Intravenous | “Participants will receive AZD8701 intravenously” NCT04504669 ↗ |
| Target | FOXP3 | “Direct targeting of FOXP3 in Tregs with AZD8701” PMID 35387780 ↗ Apr 2022 |